North Carolina macular dystrophy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| North Carolina macular dystrophy | |
|---|---|
| Synonyms | MCDR1, NCMD |
| Pronounce | |
| Specialty | Ophthalmology |
| Symptoms | Macular degeneration, vision loss |
| Complications | N/A |
| Onset | Childhood |
| Duration | Lifelong |
| Types | |
| Causes | Genetic mutation |
| Risks | |
| Diagnosis | Ophthalmic examination, genetic testing |
| Differential diagnosis | Age-related macular degeneration, Stargardt disease |
| Prevention | |
| Treatment | Low vision aids, supportive care |
| Medication | |
| Prognosis | Variable, generally stable |
| Frequency | Rare |
| Deaths | |
North Carolina Macular Dystrophy (NCMD), also known as MCDR1, is a rare genetic disorder characterized by the development of macular degeneration at birth or in early childhood, leading to varying degrees of visual impairment. This condition is notable for its autosomal dominant inheritance pattern, meaning a single copy of the altered gene in each cell is sufficient to cause the disorder. NCMD is specifically associated with mutations in the PRDM13 gene located on chromosome 6, although the exact mechanism by which these mutations lead to the symptoms of the disease is not fully understood.
Symptoms and Diagnosis[edit]
The primary symptom of North Carolina Macular Dystrophy is visual impairment, which ranges from mild to severe and is usually present from birth or develops in early childhood. The disease is characterized by the presence of drusen-like deposits and atrophic changes in the macula, the part of the retina responsible for sharp, central vision. Unlike age-related macular degeneration, NCMD symptoms typically do not progress significantly over time. Diagnosis of NCMD is primarily based on clinical examination, including the use of ophthalmoscopy to observe the characteristic macular lesions. Genetic testing can confirm the diagnosis by identifying mutations in the PRDM13 gene.
Treatment and Management[edit]
There is currently no cure for North Carolina Macular Dystrophy. Treatment focuses on managing symptoms and supporting individuals with the condition to achieve their maximum potential vision. This may include the use of low vision aids and adaptive technologies to help affected individuals cope with their visual impairments. Regular monitoring by an ophthalmologist is recommended to address any changes in vision and associated conditions.
Epidemiology[edit]
North Carolina Macular Dystrophy is a rare condition, with a higher prevalence reported in individuals of European descent. The disorder was first identified in a large family from North Carolina, which is how it received its name. However, cases have been reported worldwide, indicating that NCMD is not limited to any specific geographic region or ethnic group.
Genetics[edit]
The condition is caused by mutations in the PRDM13 gene, which plays a role in eye development. The inheritance pattern of NCMD is autosomal dominant, meaning that an individual only needs one copy of the mutated gene from one parent to be affected. There is a 50% chance of passing the condition on to offspring if one parent carries the mutation.
Research[edit]
Research into North Carolina Macular Dystrophy is ongoing, with studies focusing on understanding the underlying genetic mechanisms and finding effective treatments. Advances in gene therapy and regenerative medicine offer hope for future interventions that could potentially restore vision or halt the progression of the disease.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian